Aqur Biosciences

Aqur Biosciences is a biotechnology company focused on developing next-generation cardiovascular therapies, specifically targeting high cholesterol. The company's lead candidate, AQR-008, is an oral small molecule PCSK9 inhibitor designed to interfere with PCSK9 binding to the EGF-A domain of LDL receptors, thereby promoting LDL receptor recycling and lowering LDL cholesterol levels. Unlike existing injectable PCSK9 inhibitors, AQR-008 aims to provide a more accessible and cost-effective oral alternative for patients at risk of cardiovascular events like heart attacks and strokes. Aqur is also exploring the potential of its peptide-based technologies in oncology and immunology. The company leverages strategic collaborations with AI-driven discovery platforms and academic institutions to advance its pipeline.